SYT yields 0.27% · JNJ yields 2.13%● Live data
📍 SYT pulled ahead of the other in Year 1
Combined, SYT + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SYT + JNJ for your $10,000?
SYLA Technologies Co., Ltd., through its subsidiaries, primarily develops, constructs, sells, and manages apartments in Japan. It also engages in the land purchase, design, construction, operation, and maintenance of solar power plants. In addition, it offers real estate leasing, brokerage, and management services; and real estate crowdfunding service on the Rimawari-kun platform. Further, the company designs, develops, manufactures, and sells computers for artificial intelligence (AI) and graphics processing, as well as offers computer maintenance and management services; Rimawari-kun AI, a system that automatically collects various real estate data found online and compiles indexes; real estate investment, machine learning algorithms, robotic process automation, and business systems using the system. Additionally, it provides consulting on business automation and AI system implementation for corporations; offers consulting on real estate investment and asset management; operates and sells renewable energy data centers; and sells and maintains solar and biomass power generation equipment. The company also engages in electricity brokerage, renewable energy trading, and trade brokerage activities. The company was formerly known as SYLA Holdings Co., Ltd. SYLA Technologies Co., Ltd. was incorporated in 2009 and is headquartered in Tokyo, Japan.
Full SYT Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.